Skip to main content

EOLS

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

EOLS Price
Price Chart

Forward-looking statistics

Beta
1.10
Risk
61.50%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees267
Market cap$731.9M

Fundamentals

Enterprise value$656.1M
Revenue$275.5M
Revenue per employee
Profit margin-20.40%
Debt to equity-19.72

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.89
Dividend per share
Revenue per share$4.36
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$7M
Put-call ratio

Macro factor sensitivity

Growth+1.1
Credit+4.9
Liquidity+0.3
Inflation-1.4
Commodities+0.2
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio46.35
Price to sales2.17
P/E Ratio46.35
Enterprise Value to Revenue2.38
Price to book-89.41

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago.

Zacks Investment Research (May 7, 2025)
Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance

Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher volumes and a higher average selling price. Total sales for FY21 are expected to be approximately $99.7 million, +76% Y/Y.

Benzinga (January 26, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free